Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EVISTA

« Back to Dashboard
Evista is a drug marketed by Lilly and is included in one NDA. It is available from six suppliers. There are four patents protecting this drug.

The generic ingredient in EVISTA is raloxifene hydrochloride. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.

Summary for Tradename: EVISTA

Suppliers: see list6
2013 Sales:$823,647,000

Pharmacology for Tradename: EVISTA

Clinical Trials for: EVISTA

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
Status: Completed Condition: Osteoporosis, Postmenopausal

Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
Status: Completed Condition: Negative Symptoms of Schizophrenia in Post-menopausal Women.

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Stage IV Prostate Cancer

Long Term Effects of Raloxifene Treatment on Bone Quality
Status: Completed Condition: Osteoporosis, Post-Menopausal

Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
Status: Completed Condition: Postmenopausal Osteoporosis; Compliance

Cognition in the Study of Tamoxifen and Raloxifene
Status: Completed Condition: Cognition; Aging

Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Status: Recruiting Condition: Polycystic Ovary Syndrome

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease
Status: Completed Condition: Breast Cancer

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
Status: Completed Condition: Osteoporosis, Post-Menopausal

Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome
Status: Terminated Condition: Polycystic Ovarian Syndrome

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997RXYes6,458,811<disabled>YY<disabled>
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997RXYes<disabled><disabled>
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997RXYes6,894,064<disabled>Y<disabled>
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997RXYes8,030,330<disabled>Y<disabled>
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997RXYes6,797,719<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn